$Alzamend Neuro (ALZN.US)$ Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs Thursday, 12th December at 8:00 am • During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million • Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash • Strengthened balance sheet in preparation for five clinical trials to be initiated in 2025 Alzamend Neuro, Inc. (NASDAQ: ALZN) ("...
$Alzamend Neuro (ALZN.US)$Alzamend Neuro Tells Benzinga 'Data Confirm the Positive Topline Results Announced in June 2023 Identifying a Maximum Tolerated Dose as Assessed by an Independent Safety Review Committee'! Alzamend Neuro Tells Benzinga 'Identified Dose Is Unlikely to Require Lithium Therapeutic Drug Monitoring'
$Alzamend Neuro (ALZN.US)$EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's Benzinga· just On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023. Identified by an independent safety review committee, this MTD represents a pivotal ...
Worth keeping an eye on for a bounce next week. If the top of the GAP holds 2.22 then look for a move to test 2.98 and beyond. Larger Image: tradingview.com... $Alzamend Neuro (ALZN.US)$
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Alzamend Neuro Stock Forum
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Thursday, 12th December at 8:00 am
• During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million
• Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash
• Strengthened balance sheet in preparation for five clinical trials to be initiated in 2025
Alzamend Neuro, Inc. (NASDAQ: ALZN) ("...
Alzamend Neuro Tells Benzinga 'Identified Dose Is Unlikely to Require Lithium Therapeutic Drug Monitoring'
Benzinga· just
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023.
Identified by an independent safety review committee, this MTD represents a pivotal ...
Larger Image: tradingview.com...
$Alzamend Neuro (ALZN.US)$
No comment yet